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Some manifestations of human papillomavirus (HPV) infection are indolent 
and self-limiting, while others cause considerable morbidity. In recurrent 
respiratory papillomatosis (RRP), low-risk HPV types within the respiratory 
tract cause wart-like lesions, typically on vocal folds. The most common 
symptom is hoarseness, but stridor may also occur due to airway obstruction. 
In a minority of patients, the disease becomes aggressive and may undergo 
malignant transformation. 
Medical records were reviewed from all patients (n=32) treated for juvenile-
onset recurrent respiratory papillomatosis (JORRP) between 1975 and 1994 
at Helsinki University Hospital. Eighteen patients participated in a study 
assessing the effect of JORRP on adult voice quality and health-related 
quality of life (HRQOL). Compared to age- and gender-matched controls 
with similar smoking habits, the quality of voice in these adult patients with a 
history of JORRP was significantly lower in both acoustic and perceptual 
analyses. Significant differences emerged neither in HRQOL, nor in 
subjective voice-related handicap. 
Despite the viral etiology, treatment of RRP is based on surgery. Patients 
with frequently relapsing or otherwise aggressive disease may benefit from 
adjuvant medical therapies, such as local injections of cidofovir. Cidofovir is 
an antiviral medicine officially indicated for intravenous treatment of 
cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency 
syndrome (AIDS). Intravenous administration of cidofovir has caused 
nephrotoxic side-effects and neutropenia. Animal studies have raised 
suspicions of its carcinogenicity. According to its manufacturer, patients 
treated either by off-label indications, or by an unapproved route of 
administration (intraocular or topical) have developed severe side-effects.  
An international multicenter study collected data from 635 RRP patients, 275 
of which were treated with cidofovir. Mean follow-up after the first cidofovir 
injection was 3.3 years. Differences in incidence of upper respiratory tract 
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and tracheal malignancies were non-significant between patients treated 
with and without cidofovir. After local administration of cidofovir, no clinical 
evidence emerged for nephrotoxicity or neutropenia. 
Between 1975 and 2011, a total of 324 RRP patients underwent treatment at 
Helsinki University Hospital for laryngeal papillomas (LPs). Nine patients 
(2.8%) developed laryngeal squamous cell carcinoma (SCC). Expression of 
toll-like receptors (TLRs) 2, 4, and 9 were analyzed in laryngeal tissue 
specimens from these patients by immunohistochemistry (IHC). Controls 
were nine RRP patients without malignant transformation, 23 patients 
clinically presenting with chronic laryngitis, and 19 laryngeal SCC patients 
without pre-existing RRP. Compared to specimens from those with chronic 
laryngitis and laryngeal SCC, expression of cytoplasmic TLR4 and TLR9 was 
significantly lower in LPs. Nuclear TLR4 staining was significantly lower in 
LPs undergoing transformation into laryngeal SCC, than in LPs without 
malignant conversion. In laryngeal SCCs, high cytoplasmic staining for TLR4 
was associated with higher grade and advanced T stage. 
HPV infections are spread through direct contact from skin or mucosa during 
sexual contact, and from mother to child during labor. Five RRP patients and 
five patients with genital warts participated with six physicians and 12 nurses 
in a study investigating transmission of HPV from patients to the oral 
mucosa and surgical gloves and masks of health care personnel during 
carbon dioxide (CO2) laser treatment. HPV deoxyribonucleic acid (DNA) was 
detected by polymerase chain reaction (PCR) on the surgical gloves, but not 
on the surgical masks or oral mucosa of health care personnel. Provided that 
protection is sufficient during CO2 laser treatment, the risk for HPV 
transmission to health care personnel seems low. 
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TIIVISTELMÄ 
Osa ihmisen papilloomaviruksen (engl. human papillomavirus, HPV) 
aiheuttamista infektioista on luonteeltaan hyvänlaatuisia ja itsestään 
rajoittuvia, kun taas osa tuottaa potilaille merkittävää haittaa. Hengitysteissä 
ns. matalan syöpäriskin HPV-tyypit aiheuttavat taudin, jossa tyypillisesti 
äänihuulissa esiintyy toistuvasti hyvänlaatuisia papilloomia (engl. recurrent 
respiratory papillomatosis, RRP). Äänenkäheys on tavallisin oire, mutta 
myös myös hengenahdistusta voi esiintyä, jos papilloomat ahtauttavat 
ilmatien. Pienellä osalla potilaista tauti on aggressiivinen ja voi muuttua 
pahanlaatuiseksi. 
Tässä väitöskirjatyössä käytiin läpi kaikkien niiden potilaiden (n=32) 
sairauskertomukset, joita oli hoidettu lapsuusiällä alkaneen kurkunpään 
papillomatoosin takia HYKS korvaklinikalla vuosina 1975-1994. 
Kahdeksantoista potilasta osallistui tutkimukseen, jossa selvitettiin taudin 
vaikutuksia aikuisiän äänen- ja elämänlaatuun. Potilaiden akustisesti - ja 
aistinvaraisesti arvioitu äänen laatu oli merkittävästi heikompi kuin ikä-, 
tupakointi- ja sukupuolivakioitujen verrokkien. Subjektiivisesti arvioitu 
terveyteen liittyvä elämänlaatu ja äänihäiriön aiheuttama haitta ei poikennut 
merkittävästi potilaiden ja verrokkien välillä.  
Hengitysteiden papilloomia hoidetaan kirurgisesti vaikka tauti on viruksen 
aiheuttama. Usein toistuvassa tai muuten aggressiivisessa taudissa joudutaan 
turvautumaan ns. liitännäishoitoihin, kuten paikallisiin sidofoviiri-
injektioihin. Sidofoviiri on antiviraalinen lääkeaine, jota annetaan virallisen 
käyttöaiheen mukaan suonensisäisenä infuusiona sytomegaloviruksen 
aiheuttamaan verkkokalvontulehdukseen AIDS-potilailla. Suonensisäisessä 
käytössä sidofoviirin on todettu aiheuttavan munuaishaittoja ja 
neutropeniaa. Epäilyt sidofoviirin karsinogeenisuudesta perustuvat lähinnä 
eläinkokeisiin. Lääkkeen valmistaja on raportoinut hankalia sivuvaikutuksia 
potilailla, joilla sidofoviiria on annosteltu vastoin alkuperäistä indikaatiota, 
kuten silmään tai iholle.  
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Kansainväliseen monikeskustutkimukseen kerättiin retrospektiivisesti tiedot 
635:stä hengitysteiden papillomatoosia sairastavasta potilaasta. Näistä 275 
oli saanut sidofoviiria. Sidofoviiripotilaiden seuranta-ajan keskiarvo oli 3.3 
vuotta ensimmäisen injektion jälkeen. Sidofoviiria saaneilla 
papilloomapotilailla ei todettu enempää ylähengitysteiden - tai henkitorven 
pahanlaatuisia kasvaimia kuin niillä potilailla, joiden papilloomia hoidettiin 
ilman sidofoviiria. Tutkimuksessa ei saatu lisänäyttöä siitä, että sidofoviiri 
aiheuttaisi munuaisvaurioita tai neutropeniaa ylähengitysteiden 
papilloomien paikallisissa injektioissa. 
HYKS korvaklinikalla hoidettiin vuosina 1975-2011 yhteensä 324 
kurkunpään papillomatoosia sairastavaa potilasta, joista yhdeksälle (2.8%) 
kehittyi kurkunpään levyepiteelisyöpä. Tutkimuksessa analysoitiin tollin 
kaltaisten reseptorien (engl. toll-like receptors, TLR) 2, -4 ja -9 
immunoekspressiota näiden potilaiden papillooma- ja syöpäkudoksessa. 
Verrokkeina oli yhdeksän kurkunpään papilloomaa jotka eivät 
pahanlaatuistuneet, 23 näytettä kroonista laryngiittia sairastavilta potilailta, 
sekä 19 näytettä kurkunpään levyepiteelisyövistä joita ei edeltänyt 
papillomatoosi. Sytoplasminen TLR4- ja TLR9-ekspressio oli merkittävästi 
matalampi kurkunpään papilloomissa kuin kroonisissa laryngiiteissa tai 
kurkunpääsyövissä. Tuman TLR4-ekspressio oli merkittävästi matalampi 
niissä papilloomissa jotka muuttuivat pahanlaatuisiksi verrattuna ei-
malignisoituneisiin papilloomiin. Kurkunpään levyepiteelisyövissä korkea 
sytoplasman TLR4-ekspressio oli yhteydessä kohtalaiseen - tai huonoon 
erilaistumisasteeseen, sekä pidemmälle edenneeseen tautiin. 
HPV:n tiedetään tarttuvan iholta tai limakalvolta seksikontakteissa ja mm. 
synnytyksen yhteydessä äidiltä lapselle. Tässä tutkimuksessa analysoitiin 
PCR-menetelmällä HPV DNA:n leviämistä hoitohenkilökunnan suun 
limakalvoille, sekä leikkauskäsineisiin ja –maskeihin, kun he hoitivat 
hiilidioksidilaserilla potilaiden kurkunpään papilloomia ja genitaalialueen 
kondyloomia. Tutkimukseen osallistui viisi kurkunpään papilloomien - ja 
viisi genitaalialueen kondyloomien takia hoidettavaa potilasta, sekä kuusi 
lääkäriä ja 12 hoitajaa. HPV DNA:ta löytyi hoitohenkilökunnan hanskoista, 
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mutta ei maskeista eikä suun limakalvoilta. Löydökset viittaavat siihen, että 
hoitohenkilökunnan riski saada HPV-tartunta potilaalta 
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ABBREVIATIONS 
AIDS  acquired immunodeficiency syndrome 
AORRP  adult-onset recurrent respiratory papillomatosis 
CIN  cervical intraepithelial neoplasia 
CMV  cytomegalovirus 
CO2 carbon dioxide 
DNA  deoxyribonucleic acid 
eGFR  estimated glomerular filtration rate  
H&E  hematoxylin and eosin 
HPV human papillomavirus 
HRQOL health-related quality of life 
IHC  immunohistochemistry 
ISH in situ hybridization 
JORRP juvenile-onset recurrent respiratory papillomatosis 
LP laryngeal papilloma 
LPS  lipopolysaccharide 
mRNA messenger ribonucleic acid 
PCR polymerase chain reaction 
pRb retinoblastoma protein 
RRP  recurrent respiratory papillomatosis 
SIL  squamous intraepithelial lesion 
SCC squamous cell carcinoma 
TLR toll-like receptor 
VHI  voice handicap index 
V-RQOL voice-related quality of life 
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1 INTRODUCTION 
Recurrent respiratory papillomatosis (RRP) is a disease characterized by 
wart-like lesions within the respiratory tract, most commonly on the vocal 
folds (1). These lesions may recur at short intervals, resolve spontaneously, or 
reappear after a latent period (2, 3). For both respiratory papillomas and 
genital warts, the main causative agents are low-risk human papillomavirus 
(HPV) types 6 and 11 (4).  
Dysphonia is the most typical presenting symptom in RRP, but laryngeal 
papillomas (LPs) may also cause stridor by narrowing the airway (5, 6). Since 
no cure exists for RRP, the treatment focuses on surgical removal of 
exophytic lesions to maintain a serviceable quality and function of voice and 
to prevent airway obstruction. Few patients require tracheotomy, small 
children more often than adults (7).  
Since HPV vaccination is now available for disease prevention, it has become 
increasingly important to assess the effects of RRP on health-related quality 
of life (HRQOL) (8). Although RRP is a rare disease, its chronic nature with 
frequent relapses causes substantial morbidity in patients, as well as 
considerable costs to the healthcare system (9, 10). Irreversible vocal fold 
tissue damage, due to repeat surgery, may cause vocal symptoms even when 
remission has been achieved.  
Both commercialized HPV vaccines, Gardasil® and Cervarix®, protect from 
the most common high-risk HPV types 16 and 18 (11). Low-risk HPV types 6 
and 11 are covered only by Gardasil®, a quadrivalent vaccine which could 
markedly reduce the incidence of RRP and genital warts through widespread 
immunization. However, these vaccines are primarily indicated for the 
prevention of premalignant and cancerous anogenital lesions.  Several 
aspects, such as cost-effectiveness and cross-protection from other oncogenic 
HPV types, must be taken into account when considering national HPV 
immunization (12, 13).  
 13 
The presumed mode of HPV transmission in children with RRP is through an 
infected birth canal, although horizontal routes of transmission after birth 
also exist (14, 15). In adults, HPV infection is usually transmitted by sexual 
contact (16). HPV deoxyribonucleic acid (DNA) has been detected in the 
plume produced by carbon dioxide (CO2) laser treatment, raising questions 
as to risks of HPV transmission from patients to health care workers (17). 
Recommendations for personal protective equipment are not consistent 
between health care institutions, and personnel treating patients may be 
unaware of the infectious etiology. Case reports have described RRP in 
personnel repeatedly exposed to the CO2 laser plume during treatment of 
HPV-associated lesions (18, 19). 
RRP patients with frequently relapsing or otherwise aggressive disease, 
requiring more than four operations annually or spreading into 
extralaryngeal sites, may need adjuvant therapy (20, 21). Cidofovir 
(Vistide®) is an antiviral agent with an official indication for intravenous 
treatment of cytomegalovirus (CMV) retinitis in patients with acquired 
immunodeficiency syndrome (AIDS) (22). It has been locally injected in 
RRP, usually after surgical removal of exophytic papillomas.  
Neutropenia (23) and renal toxicity (22, 24) can occur after large doses of 
cidofovir in immunocompromized patients. Although suspicions of its 
carcinogenicity are mainly based on in vitro studies (25, 26) and animal 
models (27), malignant transformation of RRP following cidofovir treatment 
has raised questions about its safety (28). The manufacturer has prohibited 
its use outside the original indications because off-label use, such as 
administration directly onto the skin or eyes, has resulted in severe local and 
general side-effects (29). The lack of therapeutic options for RRP patients 
with aggressive disease causes patients and clinicians considerable distress. 
The malignant transformation rate of RRP has ranged from 1% to 23% (30, 
31). Several factors may contribute to the cancer risk: irradiation therapy, 
laryngopharyngeal reflux, smoking, and exposure to other carcinogens. In 
most studies, the follow-up data are either inadequately reported, or come 
from patient records in a single institution.  In RRP, dysplasia is common 
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(32). To detect those laryngeal papillomas (LPs) progressing from dysplasia 
into invasive carcinoma is only possible by obtaining biopsy specimens 
repeatedly under general anesthesia. Therefore, a biomarker able to predict 
increased risk for malignancy would be useful in detecting those RRP 
patients requiring closer follow-up. 
The aim of this study was to assess clinical features, sequelae of treatment, 
and factors contributing to malignant transformation in RRP. 
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2 REVIEW OF THE LITERATURE 
2.1 HPV 
2.1.1 GENERAL ASPECTS 
Human papillomavirus (HPV) infections have a wide spectrum of clinical 
manifestations. Some infections are self-limiting and merely indolent, 
whereas others cause significant concern, morbidity, and mortality (33, 34).  
At present, more than 170 different HPV types have undergone complete 
characterization, and new types are being found continuously (35). 
Mucosotropic HPVs have been divided into low-risk and high-risk types 
depending on their carcinogenic potential (36, 37).  
HPV infections are extremely common, they are usually transient in nature, 
and rarely become life-threatening. In a Finnish HPV Family Study, the point 
prevalence of oral HPV infection ranged from 15% to 24% during a follow-up 
of six years. High-risk HPV type 16 was most frequently detected (38). The 
majority of mucosal HPV infections resolve without treatment. Some 
individuals, however, fail to clear the infection. In recurrent respiratory 
papillomatosis (RRP), a chronic infection by low-risk HPV types may require 
frequent laryngeal surgery or securing of the airway (39).  
An estimated cumulative incidence of genital HPV infection is between 50% 
and 80% (40). The median time for clearance of cervicovaginal HPV 
infections is approximately eight months (41, 42). In 10-20% of women, 
however, genital HPV infections become persistent, with potential for 
malignant transformation (43, 44).  
High-risk HPV infections contribute to a substantial proportion of 
oropharyngeal squamous cell carcinomas (SCCs), and they are strongly 
associated with cervical intraepithelial neoplasias (CINs), and cancers of the 
cervix, vulva, vagina, and penis (33, 45-47). 
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2.1.2 HPV TRANSMISSION 
Detection of HPV deoxyribonucleic acid (DNA) in amniotic fluid, cord blood, 
and placenta suggests that exposure to HPV may already occur before birth 
(48, 49). Transmission of HPV from the infected birth canal during vaginal 
delivery is common. In a study by Rintala et al. infants were repeatedly tested 
for high-risk HPV DNA from birth until 36 months of age. Of 324 infants, 
63% had an oral mucosal sample positive for high-risk HPV at least once. 
Only 47% of infants never tested positive for genital high-risk HPV (50). 
Although persistent oral or genital HPV carriage is uncommon in childhood, 
the majority of individuals acquire HPV later in life through sexual activity 
(51).  
Association between maternal genital warts and juvenile-onset recurrent 
respiratory papillomatosis (JORRP) was already suggested in 1956 (52), and 
confirmed thereafter several times (53-55). Although HPV DNA has been 
detected in a substantial proportion of offspring from mothers with genital 
HPV lesions, only a few of these children develop RRP (56, 57). Oral sex is 
considered to be the most common mode of HPV transmission in adult-onset 
recurrent respiratory papillomatosis (AORRP). Kashima et al. reported that, 
compared to controls, patients with AORRP had more life-time sex partners 
and a higher frequency of oral sex (16). 
The personnel are constantly exposed to HPV, in specialized health care units 
treating HPV-associated lesions of the urogenital area and respiratory tract, 
but few studies have investigated the risks of HPV transmission from 
patients to personnel. HPV DNA has been detected in the CO2 laser plume 
during treatment of HPV lesions, and two case-reports have described onset 
of RRP in individual health care workers treating patients with anogenital 
condylomas (17-19, 58, 59). Virus particles dispersed in the laser plume may, 
however, be incapable of causing an infection (60). Since HPV is frequently 
present in macroscopically normal mucosa, it is often impossible to 
determine the source of infection and the point in time when a person - a 
health care worker for example - acquired HPV.  Further information is vital 
as to the actual risks of HPV transmission from patients to health care 
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personnel, as well as to the usefulness of personal protective equipment in 
preventing infection. 
2.1.3 HPV STRUCTURE AND MECHANISM OF ACTION 
Human papillomavirus (HPV) belongs to the Papovavirus family. It is an 
epitheliotropic, non-enveloped, icosahedrally-shaped virus. Its double-
stranded DNA genome is approximately 8000 base pairs in length. HPV 
DNA has three regions, designated according to the phase of infection in 
which they are expressed: an upstream regulatory region, an early (E) and a 
late (L) region. E-region consists of genes involved in viral replication and 
interaction with host cells. Some of the E-region gene products bind and 
inactivate host tumor-suppressor proteins (61). L-region genes code 
structural viral proteins. HPV infects basal cells of the epithelium, disturbs 
the normal process of cell differentiation, and triggers cell proliferation, 
leading to increased thickness of the epithelium. 
Histologically, respiratory papillomas typically present with finger-like 
projections with a fibrovascular core, and a varying level of dyskeratosis, 
parakeratosis, or dysplasia (Figure 1). Vacuolated cells with clear cytoplasmic 
inclusions, termed koilocytes, indicate viral etiology (62). Most of the larynx 
is lined by pseudostratified ciliated columnar “respiratory” epithelium, 
whereas vocal folds are covered with nonkeratinizing stratified squamous 
epithelium. A squamocolumnar junction area between them, that resembles 
the epithelial transition zone in the cervix, is a preferential localization for 
HPV-associated lesions (63). Squamous metaplastic epithelium, and areas of 





Figure 1. Histological image of a typical vocal fold papilloma with finger-like projections and a 
fibrovascular core. Image: Jaana Hagström 
2.1.4 METHODS FOR HPV DETECTION 
In situ hybridization (ISH) is a method that allows not only identification but 
also localization of a specific region of HPV DNA or messenger ribonucleic 
acid (mRNA) in a tissue specimen, using a specific chromogen or fluorescent 
labeled probe. Dot-like or punctuate positivity on microscopic examination 
means that the viral genome has integrated into the host cell nuclei. ISH is 
highly specific for HPV infection, but one of its obvious drawbacks is low 
sensitivity. Several copies of viral DNA or mRNA are required for the 
detection of HPV (64).  
In contrast to ISH, polymerase chain reaction (PCR) is a highly sensitive 
method for HPV analysis. It is based on amplification of a specific sequence 
of DNA or mRNA during several repeated cycles of heating and cooling. For 
example, a DNA sequence belonging to the highly conserved viral L1 gene 
can be detected using specific probes such as GP5/6, its extended version 
GP5+/6+, PGMY09/11, or degenerate primers MY09/11. Different HPV types 
can then be analyzed using restriction fragment length polymorphism or 
hybridization with type-specific probes. Theoretically, PCR can detect even a 
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single copy of DNA through exponential amplification (65). HPV PCR is 
more sensitive in fresh tissue biopsy specimens than in formalin-fixed 
paraffin-embedded tissue (66). Due to the exponential amplification, PCR is 
more sensitive to contamination than ISH.  
Exfoliated cells from macroscopically healthy oral mucosa can be obtained 
for HPV PCR analysis either by oral brushing or using a mouthwash (67).  
These methods cause less mucosal damage than a tissue biopsy, and they 
enable collecting cells from a larger surface area. For example, PCR can 
detect the viral L1 gene in the superficial epithelial cells during productive 
HPV infection.  
Fresh tissue biopsy may be more useful for HPV PCR when a distinct 
pathological lesion such as a malignant tumor or a respiratory papilloma is 
excised for diagnostic purposes (68). HPV status of the basal epithelial layer 
can be determined more reliably than in a specimen containing only 
exfoliated surface cells. The rest of the biopsy specimen can be processed into 
formalin-fixed, paraffin-embedded tissue blocks without shearing off the 
superficial cells. During HPV-associated carcinogenesis, viral L1 and E2 
genes may be present in low copy numbers or even be completely disrupted 
(69). Thus, an assay that amplifies the intact E6/7 region is required for 
reliable detection of a transforming high-risk HPV infection. Reverse 
trascriptase PCR targets mRNA of oncogenic E6 and E7, allowing detection 
of transcriptionally active HPV DNA (70). 
HPV seropositivity cannot determine the site of HPV infection, nor does it 
distinguish between past exposure and ongoing HPV infection. Laryngeal 
HPV infection appears to induce a weak antibody response; in one study only 
23% of RRP patients had antibodies against HPV type 6, and 33% against 
HPV type 11. HPV antibodies showed no correlation with the virus types 
detected by PCR in laryngeal papillomas (71). 
In a cohort of 588 college women, nearly half of those with an incident 
infection by HPV type 16 or 18 stayed seronegative. In some individuals, even 
persistent high-risk genital HPV infection failed to produce an antibody 
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response (72). Although HPV serology is of limited usefulness in the clinical 
setting, it is an important method for evaluating the strength and long-term 
efficacy of antibody responses produced by HPV vaccines.  
2.1.5 IMMUNOLOGICAL ASPECTS 
Oral and genital HPV infections are extremely common, but RRP is rare. It 
seems clear that genetic factors or some failure in host immunity (or both) 
play a role in the activation of latent HPV infection. Local mucosal damage 
may also expose basal epithelial cells to HPV. Stern et al. showed that in 20 
children with RRP the ratio of CD4/CD8 cells and the response of 
lymphocytes to mitogen stimulation were significantly reduced compared to 
healthy age-matched controls (73). In that study, frequent papilloma 
recurrences were also associated with an abnormal natural killer cell 
function. Gelder at al. used sequence-specific primer PCR to determine HLA 
class I and II alleles, finding HLA DRB1*0301 to be significantly more 
common in patients with RRP than in healthy controls (74). 
2.1.6 HPV-INDUCED CARCINOGENESIS 
During the early stages of HPV infection, viral E2 protein restrains 
transcription of viral oncogenes E6 and E7 (75, 76). During carcinogenic 
progression, the viral genome integrates into the host genome, and E2 is 
disrupted, leading to elevated expression of E6 and E7. Production of viral E6 
protein results in degradation of p53, a tumor-suppressor protein required 
for growth arrest following DNA damage (77); therefore, cells without 
functional p53 display genomic instability. E6 protein activates a telomerase 
enzyme which maintains the telomeric DNA at the ends of linear 
chromosomes (78). Activation of that enzyme is seen in nearly all human 
cancers and immortalized cell lines. E7 binds to the retinoblastoma protein 
(pRb), and it also interacts with several other proteins that are important 
regulators of cell cycle. 
Low-risk HPV types 6 and 11, the causative agents of RRP, are also 
responsible for the majority of genital warts. High-risk HPV types, such as 16 
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and 18, are only infrequently present in RRP, and in laryngeal carcinomas 
arising from papillomas (31). Although HPV types 6 and 11 are considered 
nononcogenic in both oropharyngeal and urogenital area, integration of the 
HPV 11 genome in carcinomas arising from LPs suggests that HPV 
contributes to the malignant transformation of RRP (79).  
Increased expression of E7 from high-risk HPV types, causing degradation of 
functional pRb, results in strong upregulation of cyclin-dependent kinase 
inhibitor p16INK4A. Overexpression of p16INK4A is used as a surrogate marker 
for HPV association in head and neck squamous cell carcinoma (SCC), 
especially tonsillar SCC (80). E7 protein from low-risk HPV types is less 
effective in binding pRb. A study by Thomas et al. compared expression 
patterns of p16INK4A between HPV-positive and -negative head and neck SCCs 
and papillomas. p16INK4A staining was typically intense, strong, diffuse, 
cytoplasmic, and nuclear in tumors harboring high-risk HPV. In contrast, 
papillomas showed a more variable focal, weak to strong basal layer or 
scattered transepithelial positive cells (81). Another study showed that 
p16INK4A immunohistochemistry was of limited usefulness in predicting 
malignant transformation of RRP (82).  
In a meta-analysis summarizing 55 studies, the overall prevalence of HPV in 
laryngeal cancer was 28% (83). The authors conclude that especially HPV 
type 16, with a prevalence of 19.8%, is significantly associated with laryngeal 
carcinoma, although the mere presence of an episomal virus does not 
indicate HPV-associated carcinogenesis.  
2.1.7 HPV VACCINES 
Two HPV vaccines are on the market. The quadrivalent HPV vaccine 
Gardasil® contains virus-like particles of the L1 protein of both low-risk (6, 
11) and high-risk (16, 18) HPV types (84). A total of three intramuscular 
injections consist of initial dose, and doses administered 2 and 6 months 
later. Another HPV vaccine Cervarix® protects from high-risk types 16 and 
18, but also from some other non-vaccine oncogenic HPV types (85, 86). The 
vaccines are designed to induce a virus-neutralizing antibody response, 
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protecting from infection. Since they contain no live virions, they are 
incapable of causing an infection. Australia was the first country to 
commence national government-funded HPV vaccination in 2007. The 
prevalence of HPV genotypes 6, 11, 16 and 18 in cervical samples from 
women aged 18 to 24 years was significantly lower in the postvaccine period 
(2010-2011) than in the prevaccine period (2005-2007) (87). Furthermore, 
comparison of the 12-month periods of 2007/2008 and 2010/2011 showed a 
decline from 18.6% to 1.9% in the presence of genital warts among women 
under age 21, based on the proportion of new patients attending the 
Melbourne Sexual Health Centre (87).  
Current evidence is sufficiently strong to conclude that HPV vaccination 
protects from precancerous cervical lesions and genital warts (88). To show 
similar advantages for the prevention of RRP takes large study populations 
from nations with widespread immunization programs, and a longer period 
of follow-up, since this disease is less common (89). Countries undertaking 
national immunization programs against both low-risk and high-risk HPV 
types are expected to reduce dramatically their incidence of RRP, or even 
eliminate the disease. A longer time is needed for a significant decline to 
occur in the incidence of HPV-associated head and neck carcinomas in the 
vaccinated age-groups, since the disease is uncommon during the first 
decades of life. 
Neutralizing antibodies against viral L1 protein cannot cure established HPV-
associated tumors. Therapeutic HPV vaccines that produce an E6/E7-specific 
immune response have been studied in both animals and humans. 
Combining these antigen-specific immunotherapies and certain 
immunomodulating agents such as toll-like receptor (TLR) agonists may well 
become an integral part of modern cancer therapies. Of 20 women with high-
grade vulvar intraepithelial neoplasia who received three or four injections of 
vaccine containing nine HPV-16 E6 and four HPV-16 E7 synthetic peptides, 
15  had responded either partially or completely 12 months later, probably as 
a result of a vaccine induced HPV-16-specific immune response (90). 
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2.2 RECURRENT RESPIRATORY PAPILLOMATOSIS 
2.2.1 CLINICAL FEATURES 
In recurrent respiratory papillomatosis (RRP), verrucous epithelial tumours 
typically present on the vocal folds, but they may spread to extralaryngeal 
sites or, in some cases, exclusively affect the oral cavity, pharynx, trachea, or 
bronchi (91). Macroscopically, papillomas may appear as exophytic 
“cauliflower” projections with an irregular surface, or abnormally thick 
epithelium with less prominent borders (Figure 2).  
Dysphonia is the most common presenting symptom, with stridor due to 
airway obstruction less frequently present (92). RRP is a disease of an 
unpredictable nature; some patients achieve remission after a single 
procedure, while others undergo several surgical debulking operations over 
years, or even decades.  
In a study by Buchinsky et al. describing 118 patients with juvenile-onset 
recurrent respiratory papillomatosis (JORRP), the total number of surgeries 
ranged from 2 to 402 per patient (93). Typically, younger age at onset is 
associated with more aggressive disease.  
According to the most recent publications, the proportion of children with 
JORRP undergoing tracheotomy ranges from 0% to 10% (10, 93-95). Early 
decannulation is advisable, since tracheotomy may iatrogenically create an 
area of mucosal metaplasia predisposing to papilloma spread to the stomal 





Figure 2. Vocal fold papillomas with a typical red dotted surface. 
2.2.2 EPIDEMIOLOGY 
Although RRP has probably presented in humans for a long period of time, it 
was not until the mid-19th century that the disease was first described in the 
medical literature (97). Based on responses from 315 American 
otolaryngologists, Derkay et al. estimated in 1995 that the incidence of RRP 
was 1.8 per 100 000 among adults and 4.3 per 100 000 among children in 
the USA (98). One study suggested a somewhat lower incidence of JORRP, 
0.36 per 100 000 in Seattle and 1.11 per 100 000 in Atlanta. That study’s 
estimate was based on identification of individual patients from medical 
records of practicing otolaryngologists in 1996 (99). Recently, Omland et al. 
reported an even lower overall incidence of JORRP, 0.17 per 100 000, in a 
Norwegian subpopulation of 2.6 million inhabitants. Incidence of adult-onset 
recurrent respiratory papillomatosis (AORRP) was 0.54 per 100 000 in a 
subpopulation of 1.1 million inhabitants (100). In that study, both groups 
showed male preponderance. Previous literature suggests that boys and girls 
are equally affected in childhood, whereas male adults predominate among 
AORRP patients (39).  
Although severe disease, with pulmonary spread and malignant 
transformation has been more frequently reported in patients with HPV type 
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11 (101), a study by Buchinsky suggested that age, rather than HPV type, is 
associated with the disease severity in children (93). 
2.2.3 SURGICAL TREATMENT 
Aggressive RRP may primarily require surgical debulking to ensure an open 
airway. More often, surgery aims at removing vocal fold papillomas in order 
to maintain acceptable voice function. Patients usually undergo surgery 
under general anesthesia with a suspension laryngoscope and a microscope 
for visualization. Several techniques for debulking are available, some of 
which may cause less vocal fold scarring.  
Micro-resectors are instruments widely used in endoscopic sinus surgery for 
the removal of bony and soft tissue. In 1999, Myer et al. described a laryngeal 
modification of a microdebrider or a “shaver,” an electric powered 
instrument with suction and irrigation combined with rotating blade (102). 
This allows safe and efficient removal of exophytic papillomas (103).  
A study describing eleven patients aged 3 to 17, found both acoustic and 
perceptual evaluation to indicate better postoperative voice outcome in their 
microdebrider group, than in their CO2 laser group (104). Other reported 
benefits of the microdebrider include shorter duration of surgery, less 
thermal injury, and no risk of airway fire or burns (105).  
Interventions that can be delicately applied in the office under local 
anesthesia, such as the 532-nm potassium titanyl phosphate laser and 585-
nm pulsed dye laser, have become popular among some clinicians (106).  
Since most studies assessing surgical treatment of RRP describe case series, 
without any control group undergoing some other surgical modality, 
comparison between techniques is difficult. Furthermore, diversity exists in 
evaluating treatment outcomes. In some studies, patients have undergone 
perceptual and acoustic voice assessment. Others have utilized RRP severity 
scores to assess disease regression. 
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2.2.4 CIDOFOVIR 
Adjuvant medical therapies for RRP include antiviral agents and 
immunomodulators. Combining adjuvant therapies and surgery is 
considered necessary in patients requiring frequent operations and those 
with a rapid or distal disease progression. In 1998, Snoeck et al. reported 
promising results from treatment of severe RRP with intralesional injections 
of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine] (107).  
Cidofovir is a cytosine nucleoside analogue, meaning that it becomes 
incorporated into the DNA and suppresses DNA replication, with a higher 
affinity against viral DNA synthesis. The official indication for cidofovir is 
intravenous treatment of cytomegalovirus (CMV) retinitis in patients with 
acquired immunodeficiency syndrome (AIDS). In addition to the herpes 
viruses, cidofovir is active against several other DNA viruses such as Epstein-
Barr virus, poxviruses, and HPVs.  
Unlabeled intravenous use of cidofovir has been reported in life-threatening 
infections of patients with severely suppressed T cell function, such as in 
adenovirus infections of leukemia patients undergoing stem cell 
transplantation (108). Topical cidofovir has been used for extensive 
molluscum contagiosum and herpes virus infections of 
immunocompromized patients unresponsive to other treatment modalities 
(109). 
In 2004, a survey of American Society of Pediatric Otolaryngology members 
reported that intralesional cidofovir had become the most common adjuvant 
therapy for children with RRP (20). Since no widely adopted 
recommendations exist for cidofovir in RRP, clinicians have varying 
protocols for dosage, frequency, and length of treatment, as well as for 
monitoring potential side-effects. Typically, concentrations have ranged from 
2.5 to 7.5 mg/ml, with an administration interval of 2 to 6 weeks (110). Some 
clinicians use cidofovir after surgical removal of papillomas, while for others 
it is the sole treatment.  
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In one randomized, double-blind placebo-controlled study, 19 patients 
received relatively low concentrations of cidofovir (children 0.3 mg/ml, 
adults 0.75 mg/ml at the start; midway into the study the US Food and Drug 
Administration allowed 5 mg/ml for everyone). At 2- and 12-month follow-
ups, both a placebo and the cidofovir group showed a significant 
improvement in Derkay Severity Scores, but with no significant differences 
emerging between groups (111). One systematic review combined results 
from 17 case series with intralesional cidofovir therapy: of 158 patients, 90 
(57%) had a complete response, 55 (35%) a partial response, and 13 (8%) no 
improvement (112). However, to assess the true benefits of cidofovir is 
difficult due to the uncontrolled nature of the studies, variation in length of 
follow-up (1 to 66 months), and diverse combinations of other adjuvant 
therapies and surgical treatments with intralesional cidofovir. 
Nephrotoxicity and neutropenia have been associated with intravenous 
cidofovir in humans (23). In one randomized, controlled study describing 
150 patients with AIDS and CMV retinitis, 58 (39%) developed asymptomatic 
proteinuria when they received intravenous cidofovir 5 mg/kg once weekly 
for two weeks, and thereafter either 3 mg/kg or 5 mg/kg once every other 
week ; serum creatinine increased in 35 patients (24%) (22). 
An intravenous toxicology study has reported carcinogenicity in rats (27). An 
in vitro study showed that two doses of cidofovir raised HPV E6 RNA levels 
8-fold in low-risk, and 20-fold in high-risk E6-expressing HPV_ve C33A 
cervical carcinoma cells (26). The authors hypothesize that cidofovir may 
increase risk for genetic instability in cells. In another study, both high-risk 
and low-risk E6-expressing, telomerase-immortalized human keratinocyte 
cell lines, when treated with cidofovir for 2 days, showed significantly 
improved long-term survival (25). 
Whether observations from these experimental models apply to human 
beings remains unclear. However, the most significant concern with 
intralesional cidofovir in RRP is the risk for malignant transformation. One 
retrospective case series analyzed laryngeal biopsy specimens obtained from 
13 RRP patients before and after cidofovir injections. Grade of dysplasia 
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tended to worsen in two (15%) of these patients after cidofovir injections, 
whereas in others the grade of dysplasia either improved or remained 
relatively unchanged. Of the 13 patients, in six (46%), the post-cidofovir 
follow-up period exceeded 5 years. The authors conclude that cidofovir 
therapy does not correlate with worsening dysplastic progression, although 
an obvious disadvantage is the lack of a control group treated without 
cidofovir (113).  
In 2011, the producer of cidofovir prohibited its off-label use, because the 
majority of newly reported side-effects, such as renal toxicity, neutropenia 
and ocular toxicity, involved the use of cidofovir for either unapproved 
indications or by an unapproved route of administration (29). Whether 
systemic toxicity was encountered in patients with RRP was not addressed. 
After this general warning from the manufacturer, 82 laryngeal surgeons 
responded to a survey addressing the use of cidofovir and its side-effects in 
2012. The authors estimated that in RRP patients with and without exposure 
to cidofovir, the incidences of upper aerodigestive tract carcinoma were 
similar. Based on these results, the RRP task force stated that intralesional 
cidofovir should still be considered in RRP patients requiring surgery every 2 
to 3 months with regular biopsy (110). 
2.2.5 OTHER ADJUVANT MODALITIES 
Interferon-α, an immunomodulatory agent usually administered by 
subcutaneous injection, has antiviral and antiproliferative effects. Both acute 
reactions (flu-like symptoms, fever, headache) and delayed adverse effects 
(pancytopenia, alopecia, hepatorenal failure, cardiac dysfunction) have 
limited its use (114). Activation of the disease following withdrawal of 
interferon-α is also a major disadvantage (115). 
Other adjuvant treatments, such as acyclovir, ribavirin, cyclo-oxygenase 
inhibitors, indole-3-carbinol and medications against laryngopharyngeal 
reflux disease, have been suggested as having some effect, but their 
usefulness in controlling the disease is difficult to evaluate due to lack of 
placebo-controlled trials (116-119). RRP is a rare disease with unpredictable 
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behavior. To prove superiority of one treatment modality over another, either 
surgical or medical, is therefore challenging, since a considerable number of 
patients should be recruited, and study groups should be similar in terms of 
disease severity. Therapeutic HPV vaccination in patients with severe RRP 
requires further investigation. A multi-center placebo-controlled, 
randomized study could clarify the potential of neutralizing antibodies 
against low-risk HPV types in controlling an aggressive disease.  
2.2.6 HEALTH-RELATED QUALITY OF LIFE 
Measuring health-related quality of life (HRQOL) has become increasingly 
important due to the development of therapeutic and preventive 
interventions and increasing health care costs. In clinical studies, the 
HRQOL instrument should be comprehensive and sensitive, with sufficient 
test-retest reliability (120).  
The 15D, a self-administered instrument for measuring HRQOL, is a 
questionnaire that takes 5 to 10 minutes to complete. It provides a 
description of the patient’s health status in 15 different dimensions: mobility, 
vision, hearing, breathing, sleeping, eating, speech, excretion (previously 
called “elimination”), usual activities, mental function, discomfort and 
symptoms, depression, distress, vitality, and sexual activity (121). Each 
dimension is divided into 5 levels from 1 (no problems) to 5 (extreme 
problems). A 15D profile shows the position of a study group in each of the 15 
dimensions. A utility score from 0 (death) to 1 (full health with no problems 
in any dimension) combines all 15 dimensions. A 15D profile of a study 
population can be compared to the sex- and gender-matched general Finnish 
population. 
JORRP appears to reduce HRQOL in children, and a marked impact has 
been reported on the psychosocial health of the family (122, 123). In adult 
patients, RRP substantially interferes with communication and work. 
Symptoms of mental disorders, such as depression, moodiness, and excessive 
tiredness were also significantly more common in RRP patients than in 
controls matched for age, sex, and smoking habits (124, 125). Studies 
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addressing HRQOL and voice-related quality of life (V-RQOL) in patients 
with RRP are listed in Table 1.   
 
Table 1. Health-related quality of life and voice-related quality of life in recurrent respiratory 
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JORRP had a 
marked impact on V-
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psychosocial health 
of the family. 
Abbreviations: (HR)QOL, (health-related) quality of life; (JO)RRP, (juvenile-onset) recurrent respiratory 
papillomatosis; SF-36, Short Form-36; VHI, Voice Handicap Index; V-RQOL, voice-related quality of 
life 
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2.2.7 FUNCTIONAL ASSESSMENT OF VOICE 
Both objective and subjective methods can be used to assess patients with 
voice disorders. Minimal basic measurements suitable for all common voice 
disorders are listed in Table 2. When clinical studies assess the degree of a 
voice disorder, or the outcome of phonosurgical procedures, uniformity in 
methodology and expression of data allows comparison between patient 
groups (127). 
Most studies have focused on assessing the quality of voice in RRP before 
and after treatment, or on comparing outcomes between surgical modalities, 
while only a few have compared the quality of voice between RRP patients 
and healthy controls. Lindman et al. compared voice quality in prepubescent 
children (n=4) with their RRP in remission to that of age- and sex-matched 
controls (128). In that study, RRP patients’ voices were more hoarse, breathy, 
and rough in perceptual evaluation, than were voices of controls. In another 
study, seven male patients with longstanding laryngeal papillomatosis had 
poorer quality of voice in perceptual analysis, than did their age- and sex-


















Table 2. A basic protocol for functional assessment of a voice disorder according to the 
committee of phoniatricians of the European Laryngological Society (127). 
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Each component is 
graded on a 4-point 
grading scale from 0 
(normal) to 3 (severe 
deviance. 
Videolaryngostroboscopy To visualize laryngeal 
pathology, and to 
assess the mode of 
vocal fold wave and 
vocal fold closure. 
A fiber-optic or a 
straight scope with a 
strobe light is 
connected to a video 
camera, a recorder 
and a monitor. 
Vocal fold closure 
(complete, partial, no 
contact) 
Mucosal wave phase 
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function. 
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the vowel /a:/ three 
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parameters of voicing. 
Prolongation of /a:/ for 






time in seconds. 
Vital capacity, the 
maximum amount of air 
(liters) a patient can 
expel after a maximal 
inspiration.  
Subjective rating by 
patient 
To measure the 
severity of voice-
related handicap in 
daily life as perceived 
by the patient. 
A questionnaire such 
as the Voice Handicap 
Index (VHI) 
The Voice Handicap 
Index comprising 30 
statements divided into 
physical, emotional, 
and functional 
subscales. Zero VHI 
points indicates lowest 
possible handicap and 
120 points maximum 
perceived handicap  
(130). 
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2.2.8  MALIGNANT TRANSFORMATION OF RRP 
The proportion of RRP patients undergoing malignant transformation has 
ranged considerably among studies, from 1.2% to 23% (Table 3). HPV types 6 
and 11 have been present in the majority of papillomas undergoing malignant 
transformation, as well as carcinomas arising from papillomas, whereas 
high-risk HPV types 16 and 18 have been infrequently detected (31). 
Histological characteristics that could differentiate papillomas undergoing 
malignant transformation from those following a less severe course have not 
been identified.  
Laryngeal dysplasia is a dynamic process with potential for progression into 
invasive carcinoma. In mild dysplasia, the cytologic and architectural atypia 
is limited to the basal / parabasal layer. In moderate dysplasia, these changes 
progress into the mid spinous layer and in severe dysplasia, to the upper 
third of the epithelium. Some pathologists classify severe dysplasia and 
carcinoma in situ, characterized by atypical changes throughout the entire 
epithelium, into the same category (131). 
In RRP, dysplasia is common. One study reviewed pathology reports and 
charts from 54 RRP patients, none of whom had undergone cidofovir 
treatment, to determine the presence and progression of dysplasia (32). Half 
the patients developed no dysplasia during follow-up. Of the 54, 14 (26%) 
presented with mild dysplasia, six (11%) with moderate dysplasia, two (4%) 
with severe dysplasia, four (7%) with carcinoma in situ, and one with SCC. Of 
24 patients, 22 (92%) with two or more operations initially presenting with 
either mild or no dysplasia did not progress beyond mild dysplasia. In some 
RRP patients, progressive dysplasia precedes invasive carcinoma, but a quick 
transformation has been reported in others, even after a long latent period 
(30). Dysplasia is, therefore, an unreliable predictor of cancer development. 
In order to assess progression of laryngeal dysplasia, the patient must 
undergo repeated biopsy procedures under general anesthesia. Malignant 
transformation may occur at the primary site of disease presentation, but 
RRP patients with pulmonary spread may be at increased risk for developing 
carcinoma (132). 
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Table 3. Representative studies estimating incidence of malignant transformation in recurrent 
respiratory papillomatosis. Among those 45 patients developing malignancy 9 (20%) were 
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Abbreviations: CA, carcinoma; HPV, human papillomavirus; RRP, recurrent respiratory papillomatosis; 
NA, not available; PCR, polymerase chain reaction 
a Two patients had undergone radiation treatment, and 2 had been treated with bleomycin for RRP 
before CA diagnosis. This study utilized the Norwegian Cancer Registry. 
b One patient had verrucous CA. 
c Two patients had verrucous CA. 
d All 42 study patients had undergone alfa-interferon treatment.  
e Seventeen cases include 8 with CA in situ. All patients with invasive laryngeal CA were smokers. 
f Increase observed in p53 and Ki-67 protein in foci of dysplasia and CA. 
g Two patients had verrucous CA, without detectable HPV in the premalignant specimens by PCR. 
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2.3  TOLL-LIKE RECEPTORS IN HPV-ASSOCIATED 
CARCINOGENESIS 
Toll-like receptors (TLR) are evolutionarily conserved receptors presented on 
cells of the human immune system. They play a key role in innate immune 
responses by detecting distinct pathogen-associated molecular patterns of 
invading microorganisms (136-139). This leads to a series of signaling events, 
including increased expression of pro-inflammatory cytokines targeted 
against the pathogen. TLRs are also presented on several cancer cells, and 
they may either promote or suppress tumor development. TLRs 2, 3, 4, and 9 
have been detected in laryngeal SCC (140, 141). Lipopolysaccharide (LPS) 
binding to TLR4 has enhanced proliferation of head and neck cancer cells 
(142, 143). In contrast, stimulation of head and neck cancer cells with OK-
PSA, an active component of streptococcal agent OK-432, induced cell-
growth inhibition. These findings suggest that OK-432 acts not only by 
enhancing anti-cancer host responses (144), but also acts on cancer cells 
directly. 
The role of TLRs in HPV-associated head and neck tumors requires further 
research. One study investigated the association between TLR expression 
and cervical HPV persistence or clearance in young women. HPV16 
infections that cleared were significantly associated with increased 
expression of TLRs 3, 7, 8 and 9, whereas dampened TLR expression was 
associated with persistent HPV infections (145). Another study showed that 
expression of TLR4 was down-regulated during progression of cervical 
neoplasia, and that TLR4 expression was inversely associated with p16INK4A 
expression (146).  
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3 AIMS OF THE STUDY 
The general objective of this study was to improve knowledge of clinical 
features, sequelae of treatment, and factors contributing to malignant 
transformation in recurrent respiratory papillomatosis (RRP). The specific 
aims were to: 
 
1. Assess clinical features, health-related quality of life, and adult voice in 
juvenile-onset recurrent respiratory papillomatosis (JORRP). 
2. Discover whether intralesional cidofovir treatment causes neutropenia, 
renal insufficiency, malignancies, or other adverse events in patients with 
RRP. 
3. Determine the rate of malignant transformation in RRP patients treated 
for laryngeal papillomas (LPs) and analyze the role of toll-like receptors 
(TLRs) 2, 4, and 9 in malignant transformation of LPs. 
4. Determine the risk of HPV transmission from patient to medical 




4 PATIENTS AND METHODS 
4.1 CLINICAL FEATURES, HEALTH-RELATED QUALITY 
OF LIFE AND ADULT VOICE IN JORRP (STUDY I) 
In Study I, medical records were reviewed for all 32 patients treated for 
juvenile-onset recurrent respiratory papillomatosis (JORRP) at Helsinki 
University Hospital between 1975 and 1994. In 2008, 18 (56%) of them 
accepted an invitation to come for an outpatient visit, and participated in the 
study. Of the 14 non-participants, two had moved away from the hospital 
district, and 12 either refused to participate or never replied to our invitation. 
The participants and the non-participants were similar with respect to male-
female ratio, age at diagnosis, and the number of phonosurgical procedures 
and tracheotomies.  
Patients underwent a regular ear-, nose, and throat examination, and had 
their larynxes visualized by a rigid 70° -angle telescope and a stroboscope. 
The videolaryngostroboscopy recordings were stored on DVD and later 
evaluated by a phoniatrician and a laryngologist blinded to the patient 
histories. The voice sample comprised a short story and pronunciation of the 
vowel [a] three times for as long as possible after maximal inspiration. A 
condenser microphone was placed 30 cm from the subject’s mouth. The voice 
samples were recorded on a DAT tape in a soundproof chamber in the 
Phoniatric Department of Helsinki University Hospital.   
A three-second sample of the second vowel [a] served for acoustic analysis in 
all except two subjects. A 2.5-second sample was used for the two subjects 
who failed to phonate for longer than 5 seconds. The first second of the vowel 
was excluded, as well as the section following the three-second sample. A 
Multi-Dimensional Voice Program served for acoustic analysis of sustained 
vowel phonations. Percent jitter is a measure of frequency perturbation, and 
percent shimmer is a measure of amplitude perturbation. Thus, a high 
percentage of jitter indicates high variation in the frequency (“pitch”) of the 
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sound wave from cycle-to-cycle, whereas a high percentage of shimmer 
indicates high variation in the amplitude (intensity) of the sound wave.  
A panel of three experienced speech and language pathologists assessed the 
voice quality perceptually by listening to the speech samples. GRBAS quality 
categories were used with a four-point grading scale from 0 (normal) to 3 
(severe deviance). Evaluation of videolaryngoscopy findings and voice quality 
analysis by acoustic and perceptual assessment are described in Table 2 (p. 
32).   
Patients filled in a Voice Handicap Index (VHI) questionnaire which 
measures voice-related handicap in daily life (130). A 15D form assessed 
health-related quality of life. The patient interview consisted of questions 
regarding occupational status, education, and the effect of voice problems on 
vocational choice and amount of sick leave. Each patient had an age- (+/- 5 
years) and gender-matched control subject with similar use / non-use of 
tobacco, who underwent the same study protocol. Eighteen control subjects 
were recruited among hospital staff members, their friends, and family 
members.  
4.2 SAFETY OF INTRALESIONAL CIDOFOVIR IN RRP 
(STUDY II) 
In 2011, all members of the European Laryngological Society were invited to 
participate in a retrospective study addressing side-effects of intralesional 
cidofovir treatment in RRP. From 11 countries, 16 otorhinolaryngology 
centers reported data from 635 RRP patients, of whom 275 were treated with 
cidofovir. The study protocol was designed by the first (R.E.A.T) and the last 
(F.G.D.) authors, representing the University Medical Center Groeningen, 
The Netherlands. Patients treated at Helsinki University Hospital (n=244) 
comprised the largest patient group reported by one single institution. 
The study consisted of two parts: a questionnaire inquiring about the general 
use of cidofovir in each participating center and a retrospective case file 
report in which hospital patient records and laboratory parameters were 
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individually reviewed for each RRP patient treated in the participating center 
between 1998 and 2011. A manual with instructions on completing the forms 
was attached to obtain consistent data from each hospital. 
In the questionnaire, each clinic described its protocol for treatment of RRP 
patients and reported the number of RRP patients treated with and without 
cidofovir. It provided details of cidofovir treatment such as concentration, 
number of administrations, maximum cumulative dose, and observed side-
effects, as well as policies for monitoring renal function and blood neutrocyte 
levels before and after treatment. 
The retrospective case file report consisted of a clinical segment with the 
following data for each individual patient: date of birth, gender, type of RRP 
(juvenile or adult onset), number of cidofovir injections, HPV type, and 
upper respiratory tract and tracheal malignancies diagnosed after onset of 
RRP. Futhermore, it covered clinical signs of renal toxicity and length of 
follow-up both after RRP diagnosis and onset of cidofovir treatment. A 
laboratory segment involved patients with cidofovir treatment only: 
parameters for kidney function (serum creatinine, normal range 0-110 
mmol/l and estimated glomerular filtration rate (eGFR), normal range 52-
max ml/min/1.73 m2) and blood neutrocyte levels (normal range 1.8-7.7 x109 
/l) were reported before and after cidofovir treatment.  
4.3 MALIGNANT TRANSFORMATION OF RRP (STUDY 
III) 
Study III reviewed hospital patient records and pathology reports from all 
RRP patients (n=324) treated between 1975 and 2011 for laryngeal 
papillomas (LPs) at Helsinki University Hospital. To confirm the number of 
RRP patients developing laryngeal SCC, approval was obtained from the 
National Institute for Health and Welfare to access the Finnish Cancer 
Registry. The Finnish Cancer Registry, founded in 1952 by Cancer Society of 
Finland, receives cancer notifications from hospitals and physicians, as well 
as from pathology and hematology laboratories. It collects and monitors data 
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on individual cancer cases and produces cancer statistics and data for 
research purposes. Statistics Finland provides annual reports on all cancer 
deaths. Thus, the Finnish Cancer Registry is virtually a complete database on 
all cancers diagnosed among the residents of Finland since 1953 (147).  
Of 324 RRP patients nine (2.8%) developed laryngeal SCC. They were all 
males with glottal SCC, aged 43 to 88 (mean 68) years at diagnosis. All 
patients had AORRP and had undergone a median of 3 operations (range 1-
7) during a mean period of 5 (range 1-9) years, before laryngeal SCC. All 
except two were smokers. In addition to these nine patients with laryngeal 
SCC, one female patient with an aggressive, extralaryngeally spread JORRP 
developed squamous cell lung carcinoma, and died soon after cancer 
diagnosis at the age of 33 years. 
Control subjects were nine RRP patients who remained free of laryngeal SCC 
(mean age 60, range 52-78), 23 patients with laryngeal squamous 
intraepithelial lesions (SILs) clinically presenting with chronic laryngitis 
(mean age 62, range 46-76), and 19 laryngeal SCC patients without pre-
existing RRP (mean age 68, range 53-86). RRP patients who stayed free of 
laryngeal SCC had been on surveillance for a mean period of 72 (range 30-
165) months after the tissue specimen was obtained, and four out of the nine 
had a smoking history. All the patients with laryngeal SILs were smokers, 
and of the 23, 15 had stayed free of laryngeal SCC during a mean follow-up of 
54 (range 6-117) months. Seven patients treated for laryngeal SILs later 
developed laryngeal SCC within 6 to 52 (mean 24) months. The mean age of 
laryngeal SCC patients without prior RRP was 68 (range 53-86) years, and all 
of them were smokers. 
Formalin-fixed, paraffin-embedded laryngeal tissue blocks from patients and 
controls were retrieved from the archives of Helsinki University Hospital 
Department of Pathology, and standard H&E stained sections prepared for 
histopathological analysis. LP tissue from five RRP patients developing 
laryngeal SCC, and seven specimens from laryngeal SCCs arising from LPs 
were available for study purposes. The study pathologist (J.H.) reviewed 
standard hematoxylin and eosin (H&E) sections, and confirmed LP tumor 
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histology characterized by koilocytes, para/hyperkeratosis, and 
papillomatous epithelium with a fibrovascular core (62). Laryngeal SCCs 
were graded into well- (G1), moderately (G2), or poorly (G3) differentiated.  
Sections (4 µm) were cut from formalin-fixed and paraffin-embedded tissue 
samples to prepare immunohistochemistry (IHC) slides. The sections were 
subjected to IHC with monoclonal TLR 2 (1:50), TLR 4 (1:50) and TLR 9 
(1:100) antibodies (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA). 
p16INK4a staining was performed with the p16INK4a ready to use antibody 
(CINtech® Histology Kit, Roche, Germany).  Intensity of immunostaining 
was scored on a scale from 0 to 3. Nuclear and cytoplasmic staining was 
separately scored for TLRs. Two researchers, including the study pathologist, 
evaluated the slides independently, blinded to the clinical data. 
4.4 TRANSMISSION OF HPV DNA FROM PATIENTS TO 
HEALTH CARE PERSONNEL (STUDY IV) 
Study IV included five RRP patients operated on for LPs at the Department 
of Otorhinolaryngology – Head and Neck Surgery, and another five patients 
undergoing treatment for genital warts at the Department of Dermatology 
and Venereology, Helsinki University Hospital. All employees selected the 
material and manufacturer of their surgical gloves, and used protective 
plastic goggles, and laser plume masks during each operation. 
RRP patients were treated in an operating room under general anesthesia. A 
CO2 laser was applied to four of the five RRP patients after microdebrider 
removal of the macroscopic papilloma tumor. Three employees, including the 
surgeon, the nurse anesthetist, and the surgical nurse, participated in the 
study during each operation. Over the whole study period, a total of three 
surgeons and nine nurses performed the LP operations.  
Two employees, a physician and a nurse, administered CO2 laser 
vaporization for urethral warts during each procedure. A total of three 
physicians and three nurses conducted the CO2 laser treatments for genital 
warts during the study period.  
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A cytobrush was used to collect oral mucosal specimens for HPV DNA testing 
from the study patients and the employees immediately before and after each 
procedure. One half of each LP biopsy specimen was processed for standard 
H&E sections, and the other half went for HPV PCR analysis. Cells were 
collected from the surface of urethral warts with a cytobrush for HPV DNA 
testing. 
After each procedure, specimens from the surgical masks and gloves were 
collected for HPV DNA analysis from all except the nurse anesthetist. A 1-
cm2 piece of each glove was cut from the area covering the top of the right 
index finger, as was a 1-cm2 piece from each mask where it covered the 
employee’s mouth. These samples were individually placed in tubes 
containing 1 ml of phosphate-buffered saline and processed for HPV PCR 
analysis and genotyping by the clinical diagnostic laboratory of Quattromed 
HTI in Tartu, Estonia. DNA integrity was confirmed by amplification of 
human -globin gene (148). Degenerated MY09/11/HMB01 primers were 
used to detect HPV by PCR (149). All positive results were genotyped by 
restriction fragment length polymorphism analysis (150). 
4.5 STATISTICAL ANALYSES 
Data are presented as mean or median values, range or real case number and 
percentage. In Study II, the interquartile range of nonparametric variables is 
presented inside brackets. In Study I, the Wilcoxon signed rank test served 
for comparison of the nonparametric acoustic and perceptual voice quality 
parameters, whereas the Mann-Whitney test enabled comparison of VHI and 
15D scores between patients and controls. The chi square test and Pearson’s 
and Spearman’s correlation tests served in analysis of associations between 
variables (Studies I, II, III). Fisher’s exact test was used to compare IHC 
scores and clinicopathological characteristics (Study III). The paired sample 
T-test enabled comparison of laboratory values before and after cidofovir 
treatment (Study II) and the Kaplan-Meier method and Fisher’s exact test 
were applied when occurrences of malignancies in the cidofovir and the non-
cidofovir group were compared. Significance level was set at 0.05. 
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4.6 ETHICS  
The Ethics Committee of Helsinki University Hospital approved Studies I, 
III, and IV. For Study II, approval was not necessary, since it only involved 
reviewing medical records. Informed written consent was given by all 
participants in Studies I and IV, but not required in Study III, since the 











5.1 CLINICAL FEATURES, HEALTH-RELATED QUALITY 
OF LIFE AND ADULT VOICE IN JORRP (STUDY I) 
Table 4 presents the main clinical characteristics of 18 patients participating 
in Study I. The median follow-up was 40.1 (range 18.0-65.6) years. All five 
patients diagnosed with juvenile-onset recurrent respiratory papillomatosis 
(JORRP) before the age of 2 years achieved remission before age 7.5 years. Of 
the four patients (22%) who had undergone tracheotomy, each was 
diagnosed with JORRP before age 5.  
 
Table 4. Main clinical characteristics of adult patients (n=18) with a history of juvenile-onset 
recurrent respiratory papillomatosis examined in Study I. Age is presented in years. 
Gender, n (%)  
    Male 




6   (33) 
Age at diagnosis 
    Mean 





Age at examination  
    Mean 





Number of laryngeal procedures  
    Median 





Tracheotomy, n (%) 
    Yes 
    No 
 
 
4   (22) 
14 (78) 
Recurrences age ≥18, n (%) 
    Yes 
    No 
 
 
10  (56) 
8    (44) 
 
Of the 18, 4 patients (22%) were suspected of having laryngeal papillomas 
during videolaryngostroboscopy examinations. The vocal fold closure was 
either complete or partial in all control subjects, whereas six patients had 
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either no contact, or vocal fold closure was impossible to assess (due to 
papilloma recurrences in two, and hyperactivity of ventricular folds in two). 
Abnormal mucosal wave phase symmetry, as well as absence of mucosal 
wave amplitude symmetry, was more common in patients, than in controls. 
Both acoustic and perceptual analyses showed poorer voice quality in 
patients than in controls. Patients had significantly higher percentage jitter 
(P=0.001) and percentage shimmer (P=0.003). The noise-to-harmonics ratio 
was also significantly higher in patients (P=0.006) (Table 5). High number of 
laryngeal procedures was statistically significantly associated with poorer 
quality of voice in acoustic analyses. In the perceptual assessment, patients’ 
values were significantly higher for grade (P<0.001), roughness (P<0.001), 
breathiness (P<0.001), and strain (P=0.017), but their mean values exceeded 
1 (slight deviance) only in grade and roughness. A statistically significant 
correlation emerged between grade and number of laryngeal procedures. 
Five patients and two control subjects had a Voice Handicap Index (VHI) 
score exceeding 30, whereas all others scored below 30. Differences in VHI 
scores between patients and controls were statistically non-significant. 
Health-related quality of life analysis indicated no statistically significant 
differences in any of the 15 dimensions between patients and controls. The 












Table 5. Comparison of main outcome measures between JORRP patients (n=18) and controls 
(n=18).  










































VHI score 21.1 13.6 NS 
Health-related 
quality of life 
15D score 0.914 0.948 NS 
Abbreviations: NS, non-significant; VHI, voice handicap index 
 
5.2 SAFETY OF INTRALESIONAL CIDOFOVIR IN RRP 
(STUDY II)  
Of all 635 patients with recurrent respiratory papillomatosis (RRP) reviewed 
in Study II, 71% were male, and 81% had adult-onset disease. The percentage 
of male patients was 53.4% in the juvenile-onset group and 75.2% in the 
adult-onset group. Thus, a statistically significant difference in male-to-
female ratio appeared between juvenile-onset and adult-onset groups. The 
mean follow-up after diagnosis was 7.7 years, and of 635 patients, 25 (3.9%) 
developed an upper airway or tracheal malignancy. Of 198 patients who had 
undergone HPV typing, 165 (83%) presented with low-risk HPV, 10 (5%) had 
high-risk HPV, seven (4%) had both low and high-risk HPV, and 10 (5%) 
were HPV negative. Six patients (3%) were positive for HPV, but the type of 
HPV was not specified.  
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A total of 275 patients had undergone intralesional cidofovir treatment, at a 
concentration ranging from 5 to 75 mg/ml. The maximum dose ranged from 
20 to 375 mg per intervention. Considerable variation occurred between 
different centers in maximum cumulative dose.  Some units defined a 
minimum of cidofovir injections (from 3 to 6), others limited the maximum 
number of injections (from 6 to 15), while some centers designed cidofovir 
treatment individually for each patient, depending on recurrences and 
symptoms. Only five centers routinely monitored renal function before and 
after cidofovir administration.   
Of 275 patients treated with intralesional cidofovir, 184 (67%) were male and 
205 (75%) had adult-onset recurrent respiratory papillomatosis (AORRP). 
The number of women (P=0.038) and of patients with juvenile-onset 
recurrent respiratory papillomatosis (JORRP) (P<0.001) was statistically 
significantly higher in the cidofovir group, than in the non-cidofovir group. 
The mean follow-up period after start of cidofovir treatment was 3.3 years 
(interquartile range 1.3-4.6 years), during which four patients (1.5%) 
developed an upper airway or tracheal malignancy. No significant differences 
emerged in the occurrence of upper airway or tracheal malignancies between 
the cidofovir (1.5%) and the non-cidofovir (5%) groups.  
None of the patients, after cidofovir treatment, developed clinical signs of 
nephrotoxicity. Although creatinine concentrations monitored after 
intralesional cidofovir treatment were statistically higher than were those 
tested before cidofovir, no significant differences emerged in the number of 
patients with creatinine values exceeding normal. No statistically significant 
differences emerged in blood neutrocyte count, eGFR, or proteinuria before 
and after cidofovir treatment. One patient had proteinuria both before and 
after cidofovir injections. Other adverse events after cidofovir treatment 
included diarrhea in two, nausea in one, chronic uveitis in one, and elevation 
of the liver enzymes aspartate aminotransferase and alanine 
aminotransferase in two patients. 
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5.3 MALIGNANT TRANSFORMATION OF RRP (STUDY 
III) 
Of 324 patients with recurrent respiratory papillomatosis (RRP), treated 
between 1975 and 2011 at Helsinki University Hospital for laryngeal 
papillomas (LPs), 9 (2.8%) developed laryngeal squamous cell carcinoma 
(SCC). Immunostaining for toll-like receptor (TLR) 2 was stronger in all 
three groups of histology (LPs, laryngeal squamous intraepithelial lesions 
(SILs), and SCCs) when compared to TLR4 and TLR9 staining intensity.  
Cytoplasmic TLR4 staining was significantly lower in LPs than in laryngeal 
SILs. Cytoplasmic TLR4 negativity, when staining was categorized as either 
negative or positive, was significantly more common in LPs than in laryngeal 
SCCs. Cytoplasmic staining for TLR9 was statistically significantly stronger 
in laryngeal SILs and laryngeal SCCs than in LPs. p16INK4a staining showed no 
statistically significant differences between histology groups. 
LPs that transformed into SCC had significantly lower scores for nuclear 
TLR4 than did LPs without malignant transformation (Figure 3). None of the 
biomarkers showed statistically significant differences between laryngeal 
SCCs arising from LPs and those without RRP etiology.  
Immunostaining for cytoplasmic TLR4 correlated significantly with tumor 
grade and T stage in laryngeal SCCs; high immunostaining for cytoplasmic 
TLR4 was typical for moderately and poorly differentiated tumors, and for 









Figure 3. Left: Nuclear TLR4 negativity in a laryngeal papilloma later transforming into squamous 
cell carcinoma. Right: Nuclear TLR4 positivity in a laryngeal papilloma without malignant 
transformation. Image: Jaana Hagström. 
5.4 TRANSMISSION OF HPV DNA FROM PATIENT TO 
HEALTH CARE PERSONNEL (STUDY IV) 
In total, 120 samples were analyzed for the presence of HPV DNA. Laryngeal 
papillomas (LPs) and genital warts were all found positive for HPV DNA. 
Results of PCR analysis are presented in Table 4. After LP procedures, one of 
the five surgeons’ glove samples tested HPV positive, and those of the 
surgical nurse for three of the five samples. After treatment of genital warts, 
all samples from the surgical gloves of both physicians and nurses were 
positive for HPV DNA that corresponded to the patient tissue specimens.  
All oral mucosa specimens from patients with genital warts tested negative 
for HPV. An oral sample from one patient with LPs was positive for HPV 
DNA before and after surgery, whereas oral specimens from two LP patients 
tested positive for HPV only after surgery. HPV DNA was absent in all of the 





Table 6. HPV DNA in specimens from patients’ oral mucosa and tumor, and the surgical 
gloves of the employees. All oral mucosa specimens and surgical mask samples of 
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6.1 JORRP AS A RISK FACTOR FOR PERMANENT 
LARYNGEAL PATHOLOGY AND VOICE 
DISTURBANCES IN ADULTHOOD 
In 18 patients previously treated for juvenile-onset recurrent respiratory 
papillomatosis (JORRP) the quality of adult voice, measured by both acoustic 
and perceptual analyses, was significantly lower than in controls. Of 18 
patients only five (28%), however, had a moderate voice-related handicap in 
daily life, according to their Voice Handicap Index (VHI) score (130). 
Vocational choice was influenced by voice quality in only one patient. 
Although the literature has reported a significantly lower health-related 
quality of life (HRQOL) in both adult (124) and juvenile (122) patients with 
active recurrent respiratory papillomatosis (RRP), our findings suggest that 
the majority of JORRP patients were able to adapt well to their disease and 
experienced no significant limitations in their adult life, despite their poorer 
quality of voice. Studies assessing the HRQOL and voice-related quality of 
life in RRP patients are listed in Table 1 (p. 30).  
Voice-quality impairment and pathological videolaryngoscopy findings 
correlated with a high number of laryngeal operations. Patients who had 
undergone numerous procedures often presented with scar formation, 
ventricular fold hyperactivity, and mucosal-wave abnormalities. However, 
the degree of laryngeal pathology we observed may not apply to the majority 
of patients treated for JORRP today. Modern surgical treatment modalities, 
such as the use of a microdebrider and a CO2 laser, have reduced 
postoperative scarring and improved treatment outcomes. The importance of 
meticulous phonosurgical techniques that preserve the underlying mucosa is 
now well-acknowledged. 
In this study, over half the patients continued to relapse in adulthood. 
However, five patients diagnosed before the age of two years achieved 
complete remission. Clearance of laryngeal papillomas in patients with an 
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early-onset disease may be due to maturation of the immune system with 
age. In four patients who underwent tracheotomy, the mean age at diagnosis 
was 2.2 (range 0.8-4.9)  years. Studies have shown that children diagnosed 
with JORRP at an early age more often end with a tracheotomy, which may 
be in part explained by the smaller diameter of the airway. However, 
extralaryngeal spread is also more common in small children with JORRP, 
suggesting that more aggressive disease is associated with younger age at 
diagnosis (94). During the last two decades, the proportion of JORRP 
patients requiring tracheotomy has ranged from 0% to 10% (10, 93-95).  The 
four patients with tracheotomies in this study were treated before modern 
treatment modalities such as the carbon dioxide (CO2) laser, were applied. 
Nowadays, at our institution a JORRP patient requiring tracheotomy is 
extremely uncommon. 
Selection bias can always emerge when patients are invited to participate in a 
study voluntarily. However, our 18 participants were a rather representative 
sample of the whole JORRP patient population (n=32) reviewed here. 
Having a large JORRP patient population for a clinical study is challenging, 
because the disease is rare. 
This study provides new insights into the natural course of JORRP and 
potential impacts of the disease in adult life. These are often the main 
concerns among parents whose children are diagnosed with JORRP. Our 
patients’ perceptions of HRQOL and voice-related handicap in adulthood 
were not strongly influenced by JORRP, although frequent surgical 
operations caused irreversible laryngeal pathology and permanent voice 
impairment. These aspects should be taken into consideration when 
evaluating the advantages of preventive measures such as HPV vaccination. 
6.2 SAFETY OF INTRALESIONAL CIDOFOVIR IN RRP 
In 2011, the producer of cidofovir announced that from April 2009 to April 
2010, 46 of 53 (87%) cidofovir adverse event reports received by the 
company involved its use either for an unapproved indication or via an 
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unapproved route of administration, such as intraocular or topical. The most 
frequent and serious reactions were renal toxicity, ocular toxicity, and 
neutropenia. Although intralesional use of cidofovir in recurrent respiratory 
papillomatosis (RRP) was not addressed, the general warning by the 
producer caused many otorhinolaryngologists to cease their administration 
of cidofovir. Members of the European Laryngological Society were soon 
asked to participate in our retrospective study, collecting information about 
the potential side-effects of cidofovir in laryngology. 
Our study is in agreement with the earlier finding that males are more often 
affected by RRP than females (95, 134). Our male preponderance was 
particularly clear in patients with adult-onset recurrent respiratory 
papillomatosis (AORRP). A substantially greater proportion of patients with 
juvenile-onset recurrent respiratory papillomatosis (JORRP), 70 of 118 
(59%), had undergone cidofovir treatment, compared to the 205 of 517 (40%) 
patients with AORRP. The greater proportion of children requiring adjuvant 
therapy may be explained by the more aggressive course of their disease, as 
well as by the smaller diameter of their airways. 
In this study, no statistically significant difference emerged in incidence of 
tracheal and upper respiratory tract malignancies between the cidofovir and 
the non-cidofovir groups. The mean duration of follow-up was, however, only 
3.3 years after the first cidofovir injection. Malignant transformation is a 
process which may take years, or even decades, and several factors such as 
exposure to tobacco and other carcinogens, age, and aggressiveness of RRP 
contribute to cancer risk. Since cidofovir patients often have a history of 
frequent relapses, some defect in their immune response may also contribute 
to the cancer risk.   
Due to the retrospective nature of the study, all cases of malignant 
transformation may not have been reported. A longer study period is needed, 
with sufficient comparison of baseline characteristics and underlying risk 
factors between patient groups, to reliably assess the impact of cidofovir on 
cancer risk.  
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Although no statistically significant differences emerged in number of 
patients with creatinine values exceeding the normal limit before and after 
cidofovir treatment, creatinine concentrations monitored after intralesional 
cidofovir treatment were statistically higher than those before cidofovir. 
Considering that cidofovir is known to be nephrotoxic, these findings suggest 
that monitoring renal function before and after cidofovir treatment is 
recommendable.  
Whether or not other reported side-effects (diarrhea, nausea, uveitis, 
elevation of liver enzymes) were associated with cidofovir remains elusive, 
since cidofovir and non-cidofovir patients were neither interviewed nor 
examined according to a standardized protocol after treatment. We found no 
association between intralesional cidofovir treatment and neutropenia. 
Although several uncontrolled trials have suggested either a partial or 
complete response with intralesional cidofovir in the majority of RRP 
patients (112), their observations may be in part explained by the natural 
course of the disease. Adjuvant medical therapies for RRP should be carefully 
considered, individually planned, and used only when the potential benefits 
are likely to outweigh the risks. Clinicians should pay attention to all 
potential side-effects, and report them adequately. 
6.3 MALIGNANT TRANSFORMATION RATE OF RRP 
AND EXPRESSION OF TLRS IN LARYNGEAL 
PAPILLOMAS CONVERTING INTO LARYNGEAL 
SCC 
According to this study, malignant transformation of RRP (recurrent 
respiratory papillomatosis) is a rare event. In Study III, nine of 324 RRP 
patients (2.8%) developed laryngeal squamous cell carcinoma (SCC). Only a 
slightly higher rate of upper respiratory tract and tracheal malignancies, 
3.9%, emerged in Study II. Assessments of the rate of malignant 
transformation in RRP are summarized in Table 3 (p. 34). The Norwegian 
Cancer Registry was utilized in one study by Lie et al., nearly 20 years ago 
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(133). They reported that of 102 patients with laryngeal papillomas (LPs), 
treated between 1950 and 1979 in Norway, seven (6.9%) were diagnosed with 
laryngeal SCC, and one RRP patient with extralaryngeal spread developed 
bronchial SCC. Of eight patients with SCC in that study, two had been 
irradiated and two had undergone bleomycin treatment. In our study, of nine 
RRP patients seven were smokers, which was likely to contribute to their 
cancer risk. Genetic factors, as well as varying exposure to different 
carcinogens, may explain the wide range of malignant transformation rates 
of RRP published, from 1.2% to 23%. Furthermore, not all estimates may be 
reliable, since follow-up data are often based on patient records from only a 
single institution.  
This study showed that the expression of cytoplasmic toll-like receptors 
(TLRs) 4 and 9 was significantly lower in LPs, than in laryngeal squamous 
intraepithelial lesions (SILs) and in laryngeal SCCs. Furthermore, all LPs 
transforming into laryngeal SCC were negative for nuclear TLR4, whereas of 
9 LPs without malignant transformation, 7 showed positive nuclear TLR4 
staining.  
One study analyzed the presence of TLR4 and p16INK4a in cervical 
intraepithelial neoplasia (CIN) and cervical carcinoma, both of which are 
strongly associated with high-risk HPV types. TLR4 expression was 
significantly stronger in normal cervical tissue and early stages of CIN, than 
in high grade CINs and cervical SCC (146). Daud et al. suggested that 
increased expression of TLRs 3, 7, 8, and 9 was associated with cervical HPV 
clearance, whereas decreased TLR expression was associated with persistent 
HPV infections (145). These findings may indicate that TLR expression is 
either down-regulated by HPV or that those individuals with deficient 
immune responses are less likely to clear their HPV infections.  
The immunohistochemical data of this study should be interpreted with 
caution, because the number of samples was limited. Laryngeal tissue 
specimens are often small. Due to the lack of tissue material, HPV typing was 
impossible. Some clinicians obtain a biopsy specimen at the first papilloma 
operation to confirm diagnosis, and thereafter only if clinical features or 
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papillomas’ growth pattern change. Retrospectively collected archival tissue 
specimens may, therefore, not ideally represent histological features of the 
whole patient population.  
Although RRP is a rare disease, and malignant transformation of LPs occurs 
infrequently, it is important to understand the mechanisms of HPV-
associated carcinogenesis in the head and neck region. In contrast to cervical 
carcinomas, no precursors have been identified to oropharyngeal SCCs, a 
substantial proportion of which harbor HPV. The role of host-defense 
mechanisms, and molecular changes preceding SCC can be analyzed in LPs 
and in laryngeal SILs, since these are both potential precursors for laryngeal 
SCC.  
Two studies have shown that binding of lipopolysaccharide (LPS) to TLR4 
induces proliferation of human head and neck cancer cell lines. In contrast, 
activation of TLR4 by OK-PSA, an active component of bacteria-derived 
immunotherapeutic agent OK-432, leads to cell-growth inhibition and 
apoptosis (142, 143). A complex interplay between host immune cells and 
epithelium may either eliminate neoplastic development or promote 
carcinogenesis. Stimulation of TLRs is already used in modern biological 
anti-cancer therapies (151). These treatment modalities are primarily 
targeted at cells of the immune system, not at tumor cells. For example, 
imiquimod, used against actinic keratosis, superficial basal cell carcinoma 
and genital warts, exerts its immomodulatory effects by binding to TLR7. 
Expression of TLRs in different types of tumor cells should be analyzed, in 
order to assess the benefits of biological cancer therapies. 
The present study reaffirmed that p16INK4a expression is neither a specific nor 
a sensitive marker for HPV infection in benign laryngeal lesions, nor is it 
useful in determining risk for malignant transformation in RRP. Here, high 
staining intensity of cytoplasmic TLR4 in laryngeal SCCs correlated with 
higher tumor grade and more advanced T stage. Conversely, an earlier study 
reported a strong positive reaction for TLR4 as typical in well or moderately 
differentiated SCCs. However, nuclear and cytoplasmic staining for TLR4 
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was not separately assessed, in that study, and 12 oral-cavity cancers were 
analyzed in addition to 27 laryngeal SCCs (152).  
6.4 TRANSMISSION OF HPV DNA FROM PATIENTS TO 
HEALTH CARE PERSONNEL  
Here, HPV DNA was transmitted from the patients to the surgical gloves of 
the employees during carbon dioxide (CO2) laser treatment of laryngeal 
papillomas (LPs) and genital warts. Direct contact between gloves and HPV-
infected tumors is not common during treatment of LPs, but when a 
laryngoscope is inserted into the mouth to allow visualization, gloves 
frequently become contaminated by saliva. Direct contamination of surgical 
gloves may occur during the examination and treatment of genital warts, and 
instruments used in the operation may indirectly contaminate gloves. 
Contamination of surgical gloves by a CO2 laser plume is possible. However, 
surgical masks located further away from the treatment area and having no 
contact with the patient or secretions, remained negative for HPV DNA.  
Including patients with genital warts was intriguing, since both diseases are 
caused by HPV types 6 and 11. Furthermore, genital warts are more common 
than LPs, and a greater number of health care personnel examine and treat 
genital HPV-associated lesions. 
HPV DNA was present in the oral mucosa specimen of only one LP patient 
preoperatively, but detected in three of five postoperatively. HPV DNA may 
have been transmitted to their oral mucosa by the CO2 laser plume, but 
endotracheal tube, laryngoscope, or surgical instruments may also have 
contaminated the upper respiratory tract mucosa. 
One study found no HPV DNA corresponding to patient-derived HPV types 
in the Petri dishes left open at a distance of 1 and 2 m from the treatment 
area, nor on the swabs from the eyeglasses and nasolabial folds of the 
operator during multilayer argon plasma coagulation treatment and the CO2 
laser ablation of genital warts (153). In another study, specimens from the 
nasolabial folds of personnel tested HPV positive in 2 of the 11 cases 
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preoperatively and in 3 of the 11 cases postoperatively, and 2 of the 5 Petri 
dishes left open as far as 2 m away from the treatment area tested positive for 
HPV DNA. However, the source of HPV DNA was not confirmed by HPV 
genotyping patients’ tissue specimens (154).  Although HPV DNA has been 
detected in the CO2 laser plume by PCR (17), one study showed that only a 
few morphologically intact cells were present in the plume collected during 
the CO2 laser treatment of genital warts. In that study, no metabolic activity, 
replication or transcription of HPV occurred during incubation of the cellular 
debris (60). 
The prevalence of HPV DNA in oral mucosa specimens from young women 
ranged in a Finnish HPV Family Study from 15% to 24% (38). In our study, 
none of the oral mucosa specimens from 18 employees tested positive for 
HPV. Case reports have described RRP in health care workers after providing 
repeated laser therapies for patients with genital HPV lesions (18, 19), but 
studies on the actual prevalence of HPV infections among health care 
personnel are few. Since HPV may persist in the oral mucosa for a long time 
without causing any symptoms, it is often impossible to determine where and 
when a person diagnosed with RRP acquired HPV, making it difficult to 
confirm any association between occupational HPV exposure and laryngeal 
HPV infection.  
A larger multicenter study with a similar protocol could have provided more 
strength to these observations, but it may have been unrewarding, 
considering that HPV appeared neither in the oral mucosa nor in surgical 
masks of the personnel. HPV DNA located outside the sampling area, of 
course, remains undetected. Theoretically, a health care worker acquiring 
HPV at the time of the procedure could be more reliably tested after a few 
weeks, during productive viral infection. However, participating personnel 
had conducted similar medical procedures before the study, most for several 
years. Re-testing the same personnel after a longer period was considered 
fruitless, since exclusion of HPV transmission outside work, through oral sex 




1. A considerable proportion of patients with juvenile-onset recurrent 
respiratory papillomatosis (JORRP) continue to relapse after puberty. 
JORRP is a risk factor for permanent laryngeal pathology and voice 
disorders. However, patients do not perceive themselves as having a 
considerable voice-related handicap or health-related quality of life 
impairment in adulthood. 
2.  A multicenter retrospective chart review found no further evidence of 
long-term nefrotoxicity, carcinogenicity, or neutropenia after 
intralesional cidofovir treatment for recurrent respiratory 
papillomatosis (RRP). 
3.  Malignant transformation of RRP is a rare event. Expression of toll-like 
receptor (TLR) 4 may be valuable in predicting malignant conversion of 
laryngeal papillomas (LPs). High cytoplasmic expression of TLR4 in 
laryngeal squamous cell carcinomas (SCCs) may be associated with a 
more aggressive disease. 
4.  Absence of HPV DNA from the surgical masks and oral mucosa 
specimens of health care personnel suggests that during carbon dioxide 
(CO2) laser treatment of LPs and genital warts, HPV transmission from 
patient to personnel is unlikely to occur. However, laser plume masks, 
surgical gloves, and protective eyewear should be essential, and 
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